Pharmanutra Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Roberto Lacorte

Directeur général

€1.9m

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	less than a year

Mises à jour récentes de la gestion

Recent updates

PDG

Roberto Lacorte (55 yo)

no data

Titularisation

€1,918,290

Compensation

Mr. Roberto Lacorte serves as Vice Chairman, Managing Director and Vice President of Pharmanutra S.p.A. Between January 1995 and April 1996, Mr. Lacorte carried out military service with the Marines. Betwe...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Andrea Lacorte	Chairman & President	no data	€2.19m	pas de données
Roberto Lacorte	Vice Chairman	no data	€1.92m	0.15% € 762.2k
Carlo Volpi	Delegate Advisor	no data	€1.77m	10.56% € 55.1m
Germano Tarantino	Scientific Director & Executive Director	12.7yrs	€586.16k	pas de données
Marida Zaffaroni	Independent Director	no data	€41.00k	pas de données
Alessandro Calzolari	Lead Independent Director	no data	€41.00k	pas de données
Giovanna Zanotti	Independent Director	no data	€41.00k	pas de données
Debora Mazzacherini	Standing Auditor	no data	pas de données	pas de données
Michele Giordano	President of Supervisory Board	less than a year	pas de données	pas de données
Pasquale Giovinazzo	Internal Member of Supervisory Board	less than a year	pas de données	pas de données

0.7yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la PHNM n'est pas considéré comme expérimenté ( 0.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Pharmanutra Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Less than half of directors are independent

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Less than half of directors are independent

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen